Smarter oversight, faster trials.
We combine advanced analytics and risk-based strategies to focus on critical data, safety signals, and operational KPIs.
Our monitoring approach spans Bioavailability/Bioequivalence (BA/BE) studies and Phase I–IV Clinical Trials, ensuring targeted oversight without compromising compliance or participant safety.
Early detection of protocol deviations, transcription errors, and fraudulent practices.
Rapid response to safety signals, adverse events, and dosing deviations.
Aligns with ICH E6(R3) principles for proportionate oversight and ICH M13A for BA/BE studies.
Real-time visibility into trial performance enables quicker corrective actions.
All monitoring activities documented and accessible for inspections by FDA, EMA, DCGI, etc.
Direct source verification, facility checks, and protocol adherence verification.
Continuous off-site review of aggregated data to detect trends and outliers.
Hybrid strategy focusing on high-risk data points, safety parameters, and operational KPIs.
Site visits or intensified review triggered only by predefined KRIs or quality events.
Focused verification on specific data points, processes, or endpoints critical to study validity.